ASH 2018 | Improved outcomes in PTCL with the use of novel agents and transplantation
Jia Ruan, MD, PhD, of Weill Cornell Medical College, New York, NY, discusses the results of a retrospective study investigating the treatment outcomes of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). Speaking at the 2018 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA, Dr Ruan explains that novel agents did not impact the overall survival of these patients, but goes on to say that patients who then underwent stem cell transplantation had improved survival outcomes. Further research in the area is needed to answer questions more definitively.
Get great new content delivered to your inboxSign up